Carcinoid heart disease

Cardiology in Review

Volumn 20, Issue 4, 2012, Pages 167-176

  Palaniswamy, Chandrasekar ^a   Frishman, William H ^a   Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

carcinoid heart disease; serotonin; somatostatin; valvular heart disease

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ACTIVIN A; ALPHA INTERFERON; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRADYKININ; CHROMOGRANIN A; CONNECTIVE TISSUE GROWTH FACTOR; CYPROHEPTADINE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; HISTAMINE; KETANSERIN; MESSENGER RNA; METHYSERGIDE; NEUROKININ A; NEUROPEPTIDE K; OCTREOTIDE; ONDANSETRON; PROSTAGLANDIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA;

ARTIFICIAL EMBOLISM; ASCITES; BRONCHOSPASM; CARCINOID SYNDROME; CARDIOVASCULAR MAGNETIC RESONANCE; CELL PROLIFERATION; CENTRAL VENOUS PRESSURE; COMPLETE HEART BLOCK; CONSTRICTIVE PERICARDITIS; CORONARY ARTERY BYPASS GRAFT; CYANOSIS; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIARRHEA; DIASTOLIC HEART MURMUR; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DYSPNEA; ELECTROCARDIOGRAPHY; EXTRACELLULAR MATRIX; FATIGUE; FLUSHING; GENETIC PREDISPOSITION; HEART RIGHT LEFT SHUNT; HEART SURGERY; HEART VALVE; HEART VALVE REGURGITATION; HEART VALVE STENOSIS; HEPATIC ARTERY; HEPATOMEGALY; HUMAN; HYPOTENSION; HYPOXIA; INFERIOR CAVA VEIN; LIVER METASTASIS; LIVER RESECTION; LUNG CIRCULATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; MYOFIBROBLAST; PATENT FORAMEN OVALE; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PULMONARY VALVE REPLACEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTRICTIVE CARDIOMYOPATHY; REVIEW; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SMOOTH MUSCLE FIBER; SODIUM RESTRICTION; ST SEGMENT ELEVATION; SYSTOLIC HEART MURMUR; THORAX RADIOGRAPHY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TRANSLUMINAL VALVULOPLASTY; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE; TRICUSPID VALVE REGURGITATION; TRICUSPID VALVE REPLACEMENT; TWO DIMENSIONAL ECHOCARDIOGRAPHY; WATER DEPRIVATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOID HEART DISEASE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART VALVE PROSTHESIS IMPLANTATION; HEART VALVES; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TRICUSPID VALVE INSUFFICIENCY; TUMOR MARKERS, BIOLOGICAL;

EID: 84862193121     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31824c866e     Document Type: Review

References (118)

1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813-829.
2. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340:858-868.
3. Isler P, Hedinger C. Metastatic carcinoid of the small intestine with severe valvular defects especially in the right part of the heart and with pulmonary stenosis; a peculiar symptom complex. Schweiz Med Wochenschr. 1953;83:4-7.
4. Thorson A, Biorck G, Bjorkman G, et al. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J. 1954;47:795-817.
5. Anderson AS, Krauss D, Lang R. Cardiovascular complications of malignant carcinoid disease. Am Heart J. 1997;134:693-702.
6. Bhattacharyya S, Toumpanakis C, Caplin ME, et al. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol. 2008;101:378-381.
7. Roberts WC, Sjoerdsma A. The cardiac disease associated with the carcinoid syndrome (carcinoid heart disease). Am J Med. 1964;36:5-34.
8. Ferrans VJ, Roberts WC. The carcinoid endocardial plaque: An ultrastructural study. Hum Pathol. 1976;7:387-409.
9. Bernheim AM, Connolly HM, Hobday TJ, et al. Carcinoid heart disease. Prog Cardiovasc Dis. 2007;49:439-451.
10. Gustafsson BI, Hauso O, Drozdov I, et al. Carcinoid heart disease. Int J Cardiol. 2008;129:318-324.
11. Artaza A, Beiner JA, Gonzalez M, et al. Carcinoid heart disease: Report of a case secondary to a pure carcinoid tumour of the ovary. Eur Heart J. 1985;6:800-805.
12. Chatterjee K, Heather JC. Carcinoid heart disease from primary ovarian carcinoid tumors. A case report and review of the literature. Am J Med. 1968;45:643-648.
13. Bernheim AM, Connolly HM, Pellikka PA. Carcinoid heart disease in patients without hepatic metastases. Am J Cardiol. 2007;99:292-294.
14. Chaowalit N, Connolly HM, Schaff HV, et al. Carcinoid heart disease associated with primary ovarian carcinoid tumor. Am J Cardiol. 2004;93:1314-1315.
15. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188-1196.
16. Gustafsson BI, Tømmeras K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation. 2005;111:1517-1522.
17. Mekontso-Dessap A, Brouri F, Pascal O, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation. 2006;113:81-89.
18. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: A mechanism for serotonin effects. J Heart Valve Dis. 2001;10:827-831.
19. Roy A, Brand NJ, Yacoub MH. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis. 2000;9:256-260; discussion 260.
20. Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006;111:674-706.
21. Møller JE, Connolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348:1005-1015.
22. Smith SA, Waggoner AD, de las Fuentes L, et al. Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J Am Soc Echocardiogr. 2009;22:883-889.
23. Frishman WH, Mogul HR, Peterson SJ. Pharmacotherapy of obesity. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 3rd ed. Minneapolis, MN: Cardiotext; 2011:397-412.
24. Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002;77:1280-1286.
25. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656-662.
26. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;57:75-81.
27. Conlon JM, Deacon CF, Richter G, et al. Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol. 1987;22:97-105.
28. Bergestuen DS, Edvardsen T, Aakhus S, et al. Activin A in carcinoid heart disease: A possible role in diagnosis and pathogenesis. Neuroendocrinology. 2010;92:168-177.
29. Bergestuen DS, Gravning J, Haugaa KH, et al. Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in patients with neuroendocrine tumors. BMC Cancer. 2010;10:6.
30. Waltenberger J, Lundin L, Oberg K, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol. 1993;142:71-78.
31. Jian B, Xu J, Connolly J, et al. Serotonin mechanisms in heart valve disease I: Serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol. 2002;161:2111-2121.
32. Møller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: Analysis of 200 cases over two decades. Circulation. 2005;112:3320-3327.
33. Bhattacharyya S, Davar J, Dreyfus G, et al. Carcinoid heart disease. Circulation. 2007;116:2860-2865.
34. Johnston SD, Johnston PW, O'Rourke D. Carcinoid constrictive pericarditis. Heart. 1999;82:641-643.
35. Shehata BM, Thomas JE, Doudenko-Rufforny I. Metastatic carcinoid to the conducting system-is it a rare or merely unrecognized manifestation of carcinoid cardiopathy? Arch Pathol Lab Med. 2002;126:1538-1540.
36. Topol EJ, Fortuin NJ. Coronary artery spasm and cardiac arrest in carcinoid heart disease. Am J Med. 1984;77:950-952.
37. Goddard MJ, Atkinson C. Cardiac metastasis from a bronchial carcinoid: Report of a case presenting with diffuse thickening of the left ventricular wall. J Clin Pathol. 2004;57:778-779.
38. Boglioli LR, Gardiner J, Gerstenblith G, et al. Carcinoid heart disease with severe hypoxia due to interatrial shunt through patent foramen ovale. Tex Heart Inst J. 1997;24:125-128.
39. Pitcher D, Fletcher P, Laszlo G, et al. Cyanosis attributable to right to left shunt in the carcinoid syndrome. Br Med J (Clin Res Ed). 1986;292:1016.
40. Castiello RJ, Lynch PJ. Pellagra and the carcinoid syndrome. Arch Dermatol. 1972;105:574-577.
41. Vidal A, Lorenzo MJ, Isidro ML, et al. Atypical thymic carcinoid in multiple endocrine neoplasia type 1 syndrome. J Endocrinol Invest. 2007;30:601-602.
42. Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet. 1998;352:799-805.
43. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92:790-795.
44. Connolly HM, Nishimura RA, Smith HC, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995;25:410-416.
45. Westberg G, Wängberg B, Ahlman H, et al. Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg. 2001;88:865-872.
46. Mansencal N, Mitry E, Forissier JF, et al. Assessment of patent foramen ovale in carcinoid heart disease. Am Heart J. 2006;151:1129.e1-1129.e6.
47. Ross EM, Roberts WC. The carcinoid syndrome: Comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med. 1985;79:339-354.
48. Feldman JM. Urinary serotonin in the diagnosis of carcinoid tumors. Clin Chem. 1986;32:840-844.
49. Feldman JM, Lee EM. Serotonin content of foods: Effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr. 1985;42:639-643.
50. Richter G, Stöckmann F, Conlon JM, et al. Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology. 1986;91:612-618.
51. Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol. 2001;13:55-58.
52. Korse CM, Taal BG, de Groot CA, et al. Chromogranin-A and N-terminal pro-brain natriuretic peptide: An excellent pair of biomarkers for diag-nostics in patients with neuroendocrine tumor. J Clin Oncol. 2009;27:4293-4299.
53. Welin S, Stridsberg M, Cunningham J, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009;89:302-307.
54. Fox DJ, Khattar RS. Carcinoid heart disease: Presentation, diagnosis, and management. Heart. 2004;90:1224-1228.
55. Zuetenhorst JM, Korse CM, Bonfrer JM, et al. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer. 2004;90:2073-2079.
56. Lundin L, Oberg K, Landelius J, et al. Plasma atrial natriuretic peptide in carcinoid heart disease. Am J Cardiol. 1989;63:969-972.
57. Bhattacharyya S, Toumpanakis C, Caplin ME, et al. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008;102:938-942.
58. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685-713; quiz 786.
59. Casazza F, Conconi B, Bongarzoni A, et al. A "never-closing" valve. Cardiac involvement in carcinoid syndrome. G Ital Cardiol. 1998;28:722.
60. Bhattacharyya S, Toumpanakis C, Burke M, et al. Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging. 2010;3:103-111.
61. Zoghbi WA, Enriquez-Sarano M, Foster E, et al.; American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777-802.
62. Lancellotti P, Moura L, Pierard LA, et al.; European Association of Echocardiography. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: Mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307-332.
63. Baumgartner H, Hung J, Bermejo J, et al.; American Society of Echocardiography; European Association of Echocardiography. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22:1-23; quiz 101.
64. Mansencal N, McKenna WJ, Mitry E, et al. Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease. Am J Cardiol. 2010;105:527-531.
65. Bhattacharyya S, Burke M, Caplin ME, et al. Utility of 3D transoesophageal echocardiography for the assessment of tricuspid and pulmonary valves in carcinoid heart disease. Eur J Echocardiogr. 2011;12:E4.
66. Mansencal N, Mitry E, Bachet JB, et al. Echocardiographic follow-up of treated patients with carcinoid syndrome. Am J Cardiol. 2010;105:1588-1591.
67. Denney WD, Kemp WE Jr, Anthony LB, et al. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J Am Coll Cardiol. 1998;32:1017-1022.
68. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588.
69. Bastarrika G, Cao MG, Cano D, et al. Magnetic resonance imaging diagnosis of carcinoid heart disease. J Comput Assist Tomogr. 2005;29:756-759.
70. Franzen D, Boldt A, Raute-Kreinsen U, et al. Magnetic resonance imaging of carcinoid heart disease. Clin Cardiol. 2009;32:E92-E93.
71. Sandmann H, Pakkal M, Steeds R. Cardiovascular magnetic resonance imaging in the assessment of carcinoid heart disease. Clin Radiol. 2009;64:761-766.
72. Mollet NR, Dymarkowski S, Bogaert J. MRI and CT revealing carcinoid heart disease. Eur Radiol. 2003;13 Suppl 6:L14-L18.
73. Díaz ML, Villanueva A, Bastarrika G, et al. Non-electrocardiogram- gated multidetector-row computed tomography findings of cardiac pathology in oncologic patients. Curr Probl Diagn Radiol. 2009;38:206-217.
74. Martos R, Ridge C, Quinn M, et al. Cardiac carcinoid: Tricuspid delayed hyperenhancement on cardiac 64-slice multidetector CT and magnetic reso-nance imaging. Ir J Med Sci. 2010;179:447-449.
75. Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-1438.
76. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663-666.
77. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606.
78. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin ana-logue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest. 1994;93:1321-1325.
79. di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77:402-408.
80. Gustafsen J, Lendorf A, Raskov H, et al. Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial. Scand J Gastroenterol. 1986;21:816-818.
81. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer. 1991;67:33-36.
82. Platt AJ, Heddle RM, Rake MO, et al. Ondansetron in carcinoid syndrome. Lancet. 1992;339:1416.
83. Oberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treat Rep. 1986;70:1297-1304.
84. Oberg K, Norheim I, Lundqvist G, et al. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin-alone or in combination with 5-FU. Acta Oncol. 1987;26:429-432.
85. Ansell SM, Pitot HC, Burch PA, et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer. 2001;91:1543-1548.
86. Ritzel U, Leonhardt U, Stöckmann F, et al. Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol. 1995;90:627-631.
87. Kvols LK, Reubi JC. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol. 1993;32:197-201.
88. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006;4:526-547.
89. Capurso G, Fazio N, Festa S, et al. Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. Crit Rev Oncol Hematol. 2009;72:110-124.
90. Pavel ME, Hainsworth JD, Baudin E, et al. For the RADIANT-2 Study Group: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised; placebo-controlled, phase 3 study. Lancet. 2011;378:2005-2012.
91. Rindi G, Caplin M. mTOR inhibitor therapy for patients with carcinoid. Lancet. 2011;378:1978-1979.
92. Grazi GL, Cescon M, Pierangeli F, et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology. 2000;47:481-486.
93. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
94. Bernheim AM, Connolly HM, Rubin J, et al. Role of hepatic resection for patients with carcinoid heart disease. Mayo Clin Proc. 2008;83:143-150.
95. Jugdutt BI, Watanabe M, Turner FW. Hepatic artery ligation in treatment of carcinoid syndrome. Can Med Assoc J. 1975;112:325-327.
96. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993;71:2624-2630.
97. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999;10:397-403.
98. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572-581.
99. Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 Guideline update on valvular heart disease: Focused update on infective endo-carditis: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:676-685.
100. Wright PW, Mulder DG. Carcinoid heart disease. report of a case treated by open heart surgery. Am J Cardiol. 1963;12:864-868.
101. McDonald ML, Nagorney DM, Connolly HM, et al. Carcinoid heart disease and carcinoid syndrome: Successful surgical treatment. Ann Thorac Surg. 1999;67:537-539.
102. Connolly HM, Schaff HV, Mullany CJ, et al. Carcinoid heart disease: Impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation. 2002;106(12 Suppl 1):I51-I56.
103. Connolly HM, Schaff HV, Mullany CJ, et al. Surgical management of left-sided carcinoid heart disease. Circulation. 2001;104(12 Suppl 1):I36-I40.
104. Ridker PM, Chertow GM, Karlson EW, et al. Bioprosthetic tricuspid valve stenosis associated with extensive plaque deposition in carcinoid heart disease. Am Heart J. 1991;121(6 Pt 1):1835-1838.
105. Ohri SK, Schofield JB, Hodgson H, et al. Carcinoid heart disease: Early failure of an allograft valve replacement. Ann Thorac Surg. 1994;58:1161-1163.
106. Schoen FJ, Hausner RJ, Howell JF, et al. Porcine heterograft valve replacement in carcinoid heart disease. J Thorac Cardiovasc Surg. 1981;81:100-105.
107. Thorburn CW, Morgan JJ, Shanahan MX, et al. Long-term results of tricuspid valve replacement and the problem of prosthetic valve thrombosis. Am J Cardiol. 1983;51:1128-1132.
108. Vahanian A, Baumgartner H, Bax J, et al.; Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28:230-268.
109. Bonow RO, Carabello BA, Chatterjee K, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the man-agement of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:e1-e142.
110. Mansencal N, Mitry E, Pillière R, et al. Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease. Am J Cardiol. 2008;101:1035-1038.
111. Mansencal N, Touhami I, Mitry E, et al. Patent foramen ovale in carcinoid heart disease. Int J Cardiol. 2010;142:e29-e31.
112. Marenco J, Naimi S, Hijazi Z, et al. Nonsurgical closure of a patent foramen ovale in a patient with carcinoid heart disease and severe hypoxia from interatrial shunting. Catheter Cardiovasc Interv. 2000;51:210-213.
113. Mottram PM, McGaw DJ, Meredith IT, et al. Profound hypoxaemia corrected by PFO closure device in carcinoid heart disease. Eur J Echocardiogr. 2008;9:47-49.
114. Hargreaves AD, Pringle SD, Boon NA. Successful balloon dilatation of the pulmonary valve in carcinoid heart disease. Int J Cardiol. 1994;45:150-151.
115. Onate A, Alcibar J, Inguanzo R, et al. Balloon dilation of tricuspid and pulmonary valves in carcinoid heart disease. Tex Heart Inst J. 1993;20:115-119.
116. Grant SC, Scarffe JH, Levy RD, et al. Failure of balloon dilatation of the pulmonary valve in carcinoid pulmonary stenosis. Br Heart J. 1992;67:450-453.
117. Castillo JG, Filsoufi F, Adams DH, et al. Management of patients undergoing multivalvular surgery for carcinoid heart disease: The role of the anaesthetist. Br J Anaesth. 2008;101:618-626.
118. Majeed F, Porter TR, Tarantolo S, et al. Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome. Eur J Echocardiogr. 2007;8:386-389.